(0.32%) 5 116.17 points
(0.31%) 38 358 points
(0.35%) 15 984 points
(-0.89%) $83.10
(5.93%) $2.04
(0.36%) $2 355.60
(0.42%) $27.65
(3.95%) $958.50
(-0.22%) $0.933
(-0.39%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
@ $1.778
発行日: 14 2月 2024 @ 23:30
リターン: 13.88%
前回のシグナル: 2月 13 - 04:27
前回のシグナル:
リターン: -3.36 %
Live Chart Being Loaded With Signals
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders...
Stats | |
---|---|
本日の出来高 | 627 712 |
平均出来高 | 1.61M |
時価総額 | 339.01M |
EPS | $0 ( 2024-03-29 ) |
次の収益日 | ( $-0.200 ) 2024-05-09 |
Last Dividend | $6.00 ( 2018-08-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.10 |
ATR14 | $0.00700 (0.34%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Apeiron Investment Group Ltd. | Buy | 147 950 | Convertible Notes |
2024-04-15 | Apeiron Investment Group Ltd. | Sell | 147 950 | Convertible Notes |
2024-04-02 | Johnson Anne Nagengast | Sell | 27 410 | Common Shares |
2024-04-02 | Rao Srinivas | Sell | 61 640 | Common Shares |
2024-04-02 | Kirpekar Sahil | Sell | 35 801 | Common Shares |
INSIDER POWER |
---|
56.52 |
Last 90 transactions |
Buy: 18 737 833 | Sell: 13 770 797 |
ボリューム 相関
ATA Inc. 相関
10 最も負の相関 | |
---|---|
ITMR | -0.949 |
AVEO | -0.939 |
GAINM | -0.933 |
XOMAO | -0.931 |
DVCR | -0.925 |
ALXN | -0.923 |
PPD | -0.923 |
GLLI | -0.923 |
MLCO | -0.923 |
ACAB | -0.922 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
ATA Inc. 相関 - 通貨/商品
ATA Inc. 財務諸表
Annual | 2023 |
収益: | $314 000 |
総利益: | $-5 000.00 (-1.59 %) |
EPS: | $-0.250 |
FY | 2023 |
収益: | $314 000 |
総利益: | $-5 000.00 (-1.59 %) |
EPS: | $-0.250 |
FY | 2022 |
収益: | $233 000 |
総利益: | $65 000.00 (27.90 %) |
EPS: | $-0.910 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.100 |
Financial Reports:
No articles found.
ATA Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.430 | 2011-06-28 |
Last Dividend | $6.00 | 2018-08-27 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $7.36 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.25 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -128.70 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.138 | 1.200 | -4.59 | -5.51 | [0 - 0.3] |
returnOnEquityTTM | -0.920 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 9.22 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.78 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.24 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0528 | -1.500 | 9.12 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -46.97 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.524 | 2.00 | -0.175 | -0.349 | [0 - 30] |
freeCashFlowPerShareTTM | -0.528 | 2.00 | -0.264 | -0.528 | [0 - 20] |
debtEquityRatioTTM | 0.0637 | -1.500 | 9.75 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -0.710 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -397.42 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -5.38 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00107 | 0.800 | -3.33 | -2.66 | [0.5 - 2] |
Total Score | -2.40 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -7.59 | 1.000 | -0.867 | 0 | [1 - 100] |
returnOnEquityTTM | -0.920 | 2.50 | -7.29 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.528 | 2.00 | -0.176 | -0.528 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.524 | 2.00 | -0.175 | -0.349 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0796 | 1.500 | -3.86 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -265.15 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.74 |
ATA Inc.
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。